EDX Medical Group is delighted to announced that the Company has appointed Martin Walton as Chief Executive Officer.
Martin Walton, currently Deputy Chairman of the Company, succeeds with immediate effect Dr Michael Hudson who as co-founder will continue to support the company as a consultant and Director, International Strategy & Partnerships, but has stepped down from the EDX Medical board.
Professor Sir Christopher Evans, OBE, founder and Chief Scientific Officer of EDX Medical, has been appointed Deputy Chairman.
Martin Walton has more than 35 years’ experience in finance and investment, latterly as vice chair, Europe and Asia Pacific, of a major Canadian bank. He has spent 15 years as an investor or officer in global life sciences companies, including Verona Pharma, Kymab, Arix Bioscience and Simbec-Orion. He has completed multiple corporate transactions creating value in private and publicly listed companies as well as building and overseeing commercial operations.
Dr Mike Owen, chairman of EDX Medical, commented: “EDX Medical is delighted to announce Martin’s appointment as CEO. This reflects the growth phase the Company has reached, and Martin’s extensive sector experience is a great asset as we drive forward our commercial operations.
“We are extremely grateful to Mike Hudson for his contribution as CEO from the earliest days of EDX Medical and look forward to him fulfilling an extremely important international and partnerships’ role.”
Professor Sir Christopher Evans, founder of EDX Medical, commented: “The board of EDX Medical has been strengthened significantly recently with the addition of three highly experienced independent non-executive directors and Martin’s financial and commercial experience made him an obvious choice to build on Mike Hudson’s success and lead the executive team as we continue to expand our commercial operations.”



